Construction Work Commenced for Drug Product Manufacturing Facility at Takasaki Plant
March 7, 2013
Tokyo, Japan, March 7, 2013-Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") will commence construction of its HA5 Plant at the Takasaki Plant (Takasaki city, Gunma, Plant Manager: Shohachi Nakajima) in May 2013.
As a part of its production site reorganization, the manufacture of some products currently made at the Fuji Plant (Suntou-gun, Shizuoka) will be transferred to the new HA5 Plant. In addition to these production transfers, the new HA5 Plant is also scheduled to manufacture those drug products currently produced at the Takasaki Plant's existing drug manufacturing facility, as well as new products that the company will hereafter develop. The HA5 Plant is designed for efficient manufacture of multiple products, with a focus on biopharmaceutical injection drugs. It will comply with the Good Manufacturing Practices (GMP) for European, U.S., and Japanese drug products, and will thus be able to supply products globally. The HA5 Plant also has been built to be base isolated system and has an emergency power supply to ensure continued operation in the event of a natural disaster. It will start operation in 2016, and begin commercial production in 2017.
Kyowa Hakko Kirin will continue to strengthen its production system to ensure the stable supply of high-quality pharmaceutical products to patients.
You can see this table by scrolling horizontally.
| Plant name: | HA5 Plant |
|---|---|
| Scale: | Four stories, with total floor space of approx. 4106 m2. Built with steel frame |
| Investment: | Approx. 4.6 billion yen |
| Purpose: | Manufacture of injection drugs |
| Completion: | Second quarter, 2014 (April to June) |
| Start of operations: | 2016 |
| Launch of commercial production: | 2017 |
| Characteristics: |
|
Contact:
Kyowa Hakko Kirin
Media Contact:
+81-3-3282-1903
or
Investors:
+81-3-3282-0009